Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This stock

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Apr 27, 2021 4:32pm

139 Views

Post# 33076456

RE:This stock

what is there to lose with nasdaq listing now? If that is only chance of seeing return let's roll dice.

Can't go lower than 50 percent from now as that is about how much money they have in cash right. If need another Reverse split at least this one will actually be for purpose of nasdaq.

woundedknee wrote: May as well be halted. Share price means nothing as it's being sold off mostly by small 100 share lots, which iIassume are by retail holders fed up with waiting. jmo

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing